- Home
- FMY vs ALGS Comparison
FMY vs ALGS Comparison
Compare FMY & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FMY | ALGS |
|---|---|---|
| Founded | 2005 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.6M | 40.6M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | FMY | ALGS |
|---|---|---|
| Price | $12.13 | $6.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $39.33 |
| AVG Volume (30 Days) | 4.0K | ★ 160.3K |
| Earning Date | 01-01-0001 | 05-05-2026 |
| Dividend Yield | ★ 6.98% | N/A |
| EPS Growth | N/A | ★ 88.30 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,186,000.00 |
| Revenue This Year | N/A | $32.20 |
| Revenue Next Year | N/A | $4.71 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.40 | $4.20 |
| 52 Week High | $12.39 | $13.69 |
Technical Indicators
Market Signals| Indicator | FMY | ALGS |
|---|---|---|
| Relative Strength Index (RSI) | 62.59 | 40.77 |
| Support Level | $11.94 | $6.38 |
| Resistance Level | $12.17 | $8.03 |
| Average True Range (ATR) | 0.13 | 0.74 |
| MACD | 0.03 | -0.11 |
| Stochastic Oscillator | 87.72 | 2.78 |
Price Performance
Historical ComparisonAbout FMY First Trust Motgage Income Fund of Beneficial Interest
First Trust Mortgage Income Fund is a United States-based diversified, closed-end management investment company. The fund's primary investment objective is to seek a high level of current income. Its secondary investment objective is to preserve capital. The fund pursues its objectives by investing predominantly in mortgage-backed securities representing part ownership in a pool of either residential or commercial mortgage loans that, in the opinion of the Fund's investment advisor, offer an attractive combination of credit quality, yield, and maturity.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.